Abstract

Trimethylamine N‐oxide (TMAO) plasma levels have been associated with atherosclerosis development in ApoE−/− mice. To better understand the mechanisms behind this association, we conducted in vivo studies looking at the effect of TMAO on different steps of atherosclerotic disease progression. Male ApoE−/− mice transfected with human cholesteryl ester transfer protein (hCETP) were fed L‐carnitine and/or methimazole, a flavin monooxygenase 3 (FMO3) inhibitor that prevents the formation of TMAO. Following 12 week treatment, L‐carnitine and TMAO plasma levels, aortic lesion development, and lipid profiles were determined. High doses of L‐carnitine resulted in a significant increase in plasma TMAO levels. Surprisingly, and independently from treatment group, TMAO levels inversely correlated with aortic lesion size in both aortic root and thoracic aorta. High TMAO levels were found to significantly correlate with smaller aortic lesion area. Plasma lipid and lipoprotein levels did not change with treatment nor with TMAO levels, suggesting that the observed effects on lesion area were independent from lipid changes. These findings suggest that TMAO slows aortic lesion formation in this mouse model and may have a protective effect against atherosclerosis development in humans.Support or Funding InformationThis study has been supported by Lonza

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.